FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:763-765 March 8, 2001 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Parkinson's disease is characterized by the progressive loss of dopamine neurons in the substantia nigra of the midbrain. These neurons project widely throughout the cerebral hemispheres, but the motor symptoms of Parkinson's disease — bradykinesia, muscle rigidity, and resting tremor — are almost certainly due to the loss of dopamine nerve terminals in the caudate and putamen nuclei (the striatum) of the basal ganglia and the unbalancing of circuits required for coordinated movement. One of the therapeutic successes of clinical neurology has been the use of levodopa, the precursor of dopamine, in patients with Parkinson's disease. In nearly all patients, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• McKhann, G. M. (2002). Neurology: Then, Now, and in the Future. Arch Neurol 59: 1369-1373 [Full Text]  
• (2001). Embryonic Neuron Transplantation for Parkinson's Disease. JWatch General 2001: 5-5 [Full Text]